Cardiovascular Systems Inc. (CSII) Hits New 52-Week High at $25.00
Cardiovascular Systems Inc. (NASDAQ:CSII)’s share price reached a new 52-week high on Tuesday . The stock traded as high as $25.00 and last traded at $24.66, with a volume of 101,633 shares changing hands. The stock had previously closed at $24.88.
Several equities analysts recently weighed in on CSII shares. Zacks Investment Research raised shares of Cardiovascular Systems from a “hold” rating to a “buy” rating and set a $21.00 target price for the company in a research note on Monday, July 4th. Needham & Company LLC reissued a “buy” rating and issued a $23.00 target price (up from $20.00) on shares of Cardiovascular Systems in a research note on Wednesday, June 29th. Leerink Swann reissued a “market perform” rating and issued a $15.00 target price (up from $13.00) on shares of Cardiovascular Systems in a research note on Saturday, May 7th. Finally, Bank of America Corp. raised shares of Cardiovascular Systems from an “underperform” rating to a “neutral” rating in a research note on Thursday, August 4th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Cardiovascular Systems currently has a consensus rating of “Buy” and an average price target of $23.71.
The firm has a 50 day moving average price of $20.98 and a 200-day moving average price of $15.63. The stock’s market capitalization is $800.59 million.
Cardiovascular Systems (NASDAQ:CSII) last issued its quarterly earnings results on Wednesday, August 3rd. The medical device company reported ($0.15) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.20) by $0.05. During the same period last year, the firm posted ($0.27) earnings per share. The business earned $48.50 million during the quarter, compared to analyst estimates of $46.01 million. Cardiovascular Systems’s quarterly revenue was up .0% compared to the same quarter last year. On average, analysts forecast that Cardiovascular Systems Inc. will post ($0.62) EPS for the current fiscal year.
In other news, SVP Paul A. Koehn sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 17th. The stock was sold at an average price of $22.17, for a total transaction of $88,680.00. Following the transaction, the senior vice president now directly owns 102,652 shares of the company’s stock, valued at $2,275,794.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Laurence L. Betterley sold 3,568 shares of the company’s stock in a transaction that occurred on Monday, August 22nd. The stock was sold at an average price of $23.96, for a total value of $85,489.28. Following the transaction, the chief financial officer now directly owns 253,031 shares in the company, valued at $6,062,622.76. The disclosure for this sale can be found here.
A hedge fund recently raised its stake in Cardiovascular Systems stock. Schwab Charles Investment Management Inc. boosted its position in Cardiovascular Systems Inc. (NASDAQ:CSII) by 3.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 98,841 shares of the medical device company’s stock after buying an additional 2,932 shares during the period. Schwab Charles Investment Management Inc. owned approximately 0.30% of Cardiovascular Systems worth $1,495,000 as of its most recent SEC filing.
Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary arterial diseases. It has developed an orbital atherectomy technology for peripheral and coronary commercial applications. Its peripheral arterial disease systems are catheter-based platforms that treat plaque types in leg arteries both above and below the knee.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.